Please assess the completion status of the following clinical trial:

Trial Title: Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the rectum~  * Tumor involving the distal 12 cm of the rectum (above the anal verge)~ * Clinically staged by endoscopic ultrasound with one of the following criteria:~    * T3-T4 disease~   * Evidence of lymph node involvement, defined by the presence of ≥ 1 enlarged peri-rectal lymph node (≥ 1 cm in size)~* No known distant metastases~PATIENT CHARACTERISTICS:~Age~* 18 to 75~Performance status~* ECOG 0-1 OR~* Karnofsky 70-100%~Life expectancy~* More than 1 year~Hematopoietic~* WBC ≥ 3,000/mm\^3~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* Bilirubin normal~* AST and ALT ≤ 2.5 times upper limit of normal~Renal~* Creatinine normal OR~* Creatinine clearance ≥ 60 mL/min~Cardiovascular~* No symptomatic congestive heart failure~* No unstable angina pectoris~* No cardiac arrhythmia~Other~* Able to receive oral medication~* No other malignancy within the past 5 years except nonmelanoma skin cancer~* No prior or concurrent significant neuropathy~* No prior allergic reaction attributed to compounds of similar chemical or biological composition to study drugs~* No ongoing or active infection~* No other concurrent uncontrolled illness~* No psychiatric illness or social situation that would preclude study compliance~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective double-method contraception during and for 3 months after study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No concurrent granulocyte-stimulating factors~Chemotherapy~* No prior chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* No prior pelvic radiotherapy~Surgery~* Not specified~Other~* No other concurrent investigational agents~* No other concurrent anticancer agents or therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).